Get the Stockscreener App
4.31
0.00%
0.00
Neuphoria Therapeutics Inc stock is traded at $4.31, with a volume of 150.55K.
It is up +0.00% in the last 24 hours and down -8.69% over the past month.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
See More
Previous Close:
$4.31
Open:
$4.35
24h Volume:
150.55K
Relative Volume:
2.85
Market Cap:
$23.29M
Revenue:
$15.00M
Net Income/Loss:
$2.71M
P/E Ratio:
3.387
EPS:
1.2725
Net Cash Flow:
$-2.89M
1W Performance:
-4.01%
1M Performance:
-8.69%
6M Performance:
+10.80%
1Y Performance:
-34.89%
1-Day Range:
$3.95
$4.4295
1-Week Range:
$3.95
$4.55
52-Week Range:
$3.645
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Name
Neuphoria Therapeutics Inc
Sector
Industry
Phone
781-439-5551
Address
100 SUMMIT DR, BURLINGTON
Compare NEUP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
4.31 | 23.29M | 15.00M | 2.71M | -2.89M | 1.2725 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-28-23 | Reiterated | Maxim Group | Buy |
| Jan-10-22 | Initiated | Berenberg | Buy |
| Jan-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-22 | Initiated | Evercore ISI | Outperform |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
View All
Neuphoria Therapeutics Inc Stock (NEUP) Latest News
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neuphoria Therapeutics Inc (NEUP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neuphoria Therapeutics Inc (NEUP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neuphoria Therapeutics Inc (NEUP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NEUP Q1 2026 Earnings: Surprise EPS Beat Highlights Cost Discipline Despite Pre-Revenue StatusOne-Time Loss Impact - lwvtexas.org
Neuphoria Therapeutics Inc. Financial Disclosures & SEC Filings - TradingView
NEUP Q1 2026 Earnings: EPS Surprises with 90.9% Beat Amid No RevenueBook Value Growth - The Legal Advocate
NEUP Q1 2026 Earnings: Significant EPS Beat Amidst Revenue AbsenceCapex Guidance - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower as Consolidation Continues Near SupportFlat Correction - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower Amid Consolidation Near SupportBollinger Band - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowed Loss Surprises as Pre-Revenue Stage ContinuesPreliminary Results - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowing Losses Beat Estimates Sharp, Yet Shares SlipRevenue Guidance Update - The Legal Advocate
Neuphoria Therapeutics (NEUP) Holds Steady Near Support – Can the Range Hold?Fibonacci Arc - newsline.com
Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial - TipRanks
Neuphoria Therapeutics (NEUP) Slips Amid Sector Headwinds – Key Support Levels in FocusSize Factor - The Legal Advocate
Neuphoria Therapeutics (NEUP) Soars 7%: Key Levels to Watch After Bullish BreakoutKey Reversal Day - Newser
NEUP Q1 2026 Earnings: Wider-Than-Expected Loss Narrows Sharply as Clinical Pipeline Progress Drives Investor OptimismEPS Surprise History - The Legal Advocate
NEUP Q1 2026 Earnings: Steeper-Than-Expected Loss Narrowing Fuels Post-Report RallyEarnings Surprise Score - Newser
What Neuphoria Therapeutics (NEUP)'s +1.62% Jump Means for Investors 2026-05-21Wave Extension - The Legal Advocate
NEUP Stock Moves Higher as Traders Focus on Neuphoria’s Cash Runway - Bez Kabli
Neuphoria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Why Neuphoria Therapeutics (NEUP) Just Dropped -6.89% — What to Watch 2026-05-17Real Trader Network - Newser
NEUP Downgraded by HC Wainwright & Co. -- Rating Updated to Neut - GuruFocus
Key facts: NEUP BNC210 Fails; SAD Halted, PTSD Paused; Q2 Loss $1.12 - TradingView
Neuphoria Therapeutics Inc expected to post a loss of $1.12 a shareEarnings Preview - TradingView
Deal Dispatch: GoPro Retains Houlihan Lokey In Strategic Review, Brookfield Buys World Freight Company, YesCare Corp. Bankruptcy - Benzinga
Neuphoria Therapeutics Inc. Q1 2026 10-Q Report: Financials, Risk Disclosures, and Strategic Outlook - Minichart
H.C. Wainwright Downgrades Neuphoria Therapeutics(NEUP.US) to Hold Rating - Moomoo
Neuphoria Therapeutics Inc. 3Q 2026: Revenue $0 EPS $(0.09) — 10-Q Summary - TradingView
Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Neuphoria Therapeutics Inc. (NEUP) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
How Neuphoria Therapeutics (NEUP) performance compares to expectations (Slight Dip) 2026-05-11Value ETF - newsline.com
NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition - MSN
How sustainable is Neuphoria Therapeutics (NEUP) earnings momentum | Q1 2026: Better Than Expected - newser.com
How Neuphoria Therapeutics (NEUP) adapts when conditions change (Smart Money Flows) 2026-05-05Senior Analyst Forecasts - newser.com
NEUP Neuphoria Therapeutics reports narrower than expected Q1 2026 loss, shares climb 2.65 percent in today’s trading.Verified Analyst Reports - newser.com
Whats the outlook for Neuphoria Therapeutics Incs sectorInsider Selling & High Yield Equity Trading Tips - baoquankhu1.vn
Decliners Report: Is Neuphoria Therapeutics Inc impacted by rising rates2026 Institutional Moves & Verified Entry Point Detection - baoquankhu1.vn
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
New Highs: Whats the outlook for Neuphoria Therapeutics Incs sectorFed Meeting & Verified Momentum Stock Watchlist - baoquankhu1.vn
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
Earnings Report: Is Neuphoria Therapeutics Inc vulnerable to short sellers2026 Weekly Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Big Money Moves: Is Neuphoria Therapeutics Inc a good ESG investment2026 Technical Patterns & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Is Neuphoria Therapeutics (NEUP) Stock a Top Performer | Price at $4.36, Down 1.25%Expert Verified Trades - Xã Thanh Hà
Why Did NEUP Stock Surge 64% Today? - MSN
How does macroeconomics affect Neuphoria Therapeutics (NEUP) Stock | Price at $4.78, Up 1.27%Arms Index - The Legal Advocate
NEUP Stock Analysis: Neuphoria Therapeutics gains 7.04 percent to hit 4.41 mark - newsline.com
Neuphoria Therapeutics Inc Stock (NEUP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):